Bellevue Medtech & Services (CH)

Medtech & Services is an investment in 10% of global gross domestic product: Healthcare sector excluding drugs

Bottom line: above-average and steady growth compared to the broad market

Focusing on profitable, liquid mid and large cap companies with an established product portfolio

Please select a share class.

Please find a more detailed description of share classes here.

Investment Focus

ISIN-No. CH0113817040

The Fund invests worldwide in companies active in the medical technology and healthcare services sector. Stock selection is based on fundamental company analysis, focusing in particular on the medical benefits and the potential savings for the healthcare system as well as the expected market potential of a company’s products and services.

Indexed performance (as at: 03.12.2021)

NAV: CHF 3'918.83 (02.12.2021)


Fonds (Brutto)
01 Jan 2010 - 01 Jan 2010
An error occurred - no data to display

Rolling performance (02.12.2021)

DT-CHFBenchmark
02.12.2020 - 02.12.202119.59%17.54%
02.12.2019 - 02.12.20205.76%8.15%
02.12.2018 - 02.12.20197.31%11.05%
02.12.2017 - 02.12.201828.63%17.36%

Annualized performance (02.12.2021)

DT-CHFBenchmark
1 year19.59%17.54%
3 years10.69%12.14%
5 years18.36%15.99%
10 years15.84%13.08%
Since Inception p.a.12.74%11.53%

Cumulative performance (02.12.2021)

DT-CHFBenchmark
1M-6.63%-4.96%
YTD17.37%15.91%
1 year19.59%17.54%
3 years35.72%41.16%
5 years132.42%110.04%
10 years335.63%242.24%
Since Inception291.88%246.51%

Annual performance

DT-CHFBenchmark
20207.20%9.32%
201922.75%24.44%
201816.42%7.00%
201727.26%22.48%

Investment Focus

The Fund invests worldwide in companies active in the medical technology and healthcare services sector. Aim is to provide investors an attractive Healthcare Fund solution by investing in the entire healthcare universe with the exclusion of drug makers. Experienced sector specialists focus on profitable, liquid mid- and large-cap companies with an established product portfolio as well as fast growing small-cap companies with leading-edge technology offering. Stock selection is based on fundamental company analysis, focusing in particular on the medical benefits and the potential savings for the healthcare system as well as the expected market potential of a company’s products and services. A global network of experts spanning scientific and industrial fields supports the Management Team in forming opinions and making investment decisions. The selection of the portfolio companies is entirely bottom-up, independent of benchmark weightings.Show moreShow less

Investment suitability & Risk

SRRI

Low risk

High risk

The Fund’s investment objective is to generate attractive and competitive long-term capital growth. It is particularly suited to investors with an investment horizon of at least 5. The Fund is exposed to the risks typical of equity investments.

General Information

Investment ManagerBellevue Asset Management AG
CustodianZürcher Kantonalbank
Fund AdministratorSwisscanto Fondsleitung AG
AuditorErnst & Young AG
Launch date03.03.2008
Year end closing30. Sep
NAV CalculationDaily "Forward Pricing"
Cut of time15:00 CET
Management Fee1.20%
Subscription Fee (max.)2.50%
Performance Fee10.00% (with High Water Mark)
ISIN numberCH0113817040
Valor number11381704
BloombergADAGMEI SW
WKNA1C20J

Key data (30.11.2021, base currency CHF)

Beta1.17
Volatility27.50
Tracking error9.33
Active share34.73
Correlation0.95
Share ratio0.55
Information ratio-0.07
Jensen's alpha-3.40
No. of positions45

Top 10 positions

United Health Group
Abbott Laboratories
Intuitive Surgical
Danaher
Humana
Edwards Lifesciences
Thermo Fisher
Boston Scientific
Dexcom
Anthem
14.8%
9.2%
5.0%
4.8%
4.3%
4.0%
3.9%
3.9%
3.7%
3.5%

Market capitalization

1 - 2 bn
2 - 5 bn
5 - 15 bn
15 - 20 bn
> 20 bn
Others
0.4%
1.7%
5.4%
5.1%
88.2%
-0.8%

Geographic breakdown

United States
Switzerland
Others
Cash
96.8%
4.6%
2.5%
-3.9%

Breakdown by sector

Healthcare
Cash
103.9%
-3.9%

Opportunities

  • Digitalization of the healthcare sector is boosting medtech companies’ growth and earnings.
  • Focusing on profitable, liquid mid and large-cap companies with an established product portfolio as well as on rapidly growing small-cap businesses delivering cutting-edge technology.
  • Managed care profits from the privatization of the health insurance sector and lower treatment costs.
  • Minimally invasive techniques gaining ground – shorter treatment times reduce healthcare costs.
  • Bellevue - Healthcare pioneer since 1993 and today one of the biggest independent investors in the sector in Europe.

Risks

  • Equities are subject to price fluctuations and so are also exposed to the risk of price losses.
  • The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
  • The fund may invest in financial instruments that might have a relatively low level of liquidity, which can in turn affect the fund’s liquidity.
  • Investing in emerging markets entails the additional risk of political and social instability.
  • Increased opportunities through possible derivative transactions go hand in hand with increased risk of loss

October was a very pleasing month for the Bellevue Medtech & Services (CH) Fund (+6.3%). The fund sailed past its benchmark (+3.3%), the broader healthcare sector (+2.3%) and the overall stock market (+3.7%). Healthcare services contributed 4.4% to the fund's monthly performance, medtech stocks 1.9%.

US health insurers Humana (+16.8%), UnitedHealth (+15.7%), Anthem (+14.6%) and Centene (+12.2%) made a big contribution to the fund's positive performance in both absolute and relative terms. Insured costs for COVID-19 treatments during the “Delta wave” of new infections were more than offset by a significant drop in non-coronavirus-related health costs, which allowed health insurers to beat consensus profit estimates for the third quarter by a wide margin. Health insurers also provided some initial positive guidance for 2022 with their earnings reports and investors were pleased with what they heard. In October, 13 US senators – including 8 from the Democratic party – vehemently opposed any cuts in payments to the Medicare Advantage program, the US health insurance plan for the elderly. This is a clear political signal that strengthens the Medicare Advantage program, in which 44% of all US citizens age 65 and older are now enrolled.

Shares of the two digital health companies Inspire Medical (+13.6%) and M3 (-19.5%) moved in different directions. The Japanese company M3 hurt the fund's monthly performance. Its weakness had more to do with the general market environment in Japan than with the company’s fundamentals.

The positive contribution of medtech companies to the fund's performance is mostly attributable to the ongoing third-quarter reporting season. Dexcom (+11.9%), Intuitive Surgical (+7.0%), Abbott (+7.5%) and Edwards Lifesciences (+3.9%) had no problems beating investors’ low expectations. The wave of Delta infections in July and August had a slightly negative impact on corporate earnings. Medical procedures showed some sequential weakness but were still at higher levels compared to the third quarter of 2019. All medical technology companies also reported a steady recovery in the number of interventions in September and October and this positive news confirms our investment case. Despite investor concerns about a staffing crisis at hospitals and supply chain disruptions (e.g. shortage of electronic components), these have not proven to be material factors and most companies have so far managed them very well. Boston Scientific (-2.4%) was marked down because the third-quarter sales growth figures it announced on the occasion of its investor day failed to beat its previously reduced guidance.

The life sciences tools company Thermo Fisher (+8.8%) beat consensus expectations for the third quarter and raised its full-year guidance for 2021 and 2022. All performance figures in CHF.

Vaccination rates in key medtech & services markets (North America, Europe and Japan) were slightly higher at the end of October. Between 69% and 81% of the population in major Western European countries have already received at least one dose of a coronavirus vaccine. In the US, 66% of the total population is vaccinated and in Japan 78%.

Widespread availability COVID-19 vaccines, a growing number of people who have recovered from coronavirus and newly available drugs that reduce the need for emergency or hospital care are important prerequisites for an upturn in elective interventions during the final quarter of 2021 and into the coming year. Regions with low vaccination rates could experience a renewed surge in hospital admissions during the next few months.

In the healthcare services segment, we believe US health insurers offer the most upside potential. Major value drivers are progressive privatization (Medicare Advantage, Medicaid), a larger pool of insured persons (commercial), the vertical integration of services providers, and efficiency gains (digitalization reduces administrative costs). Hospitals stand to benefit from the normalization of elective procedures.

We see substantial upside potential in medtech stocks thanks to their strong innovation, which is particularly evident in the latest products for diabetes therapy, minimally invasive heart valve repair and replacement procedures, and surgical robots.

Past performance is not a reliable indicator of future results and can be misleading. As the sub-fund is denominated in a currency that may differ than an investor’s base currency, changes in the rate of exchange may have an adverse effect on prices and incomes. Performance is shown net of fees and expenses for the relevant share class over the reference period. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. Individual costs are not taken into account and would have a negative impact on the performance. With an investment amount of EUR 1,000 over an investment period of five years, the investment result in the first year would be reduced by the front-end load of up to EUR 50 (5%) as well as by additional individual custody charges. In subsequent years, the investment result would also be reduced by the individual custody account costs incurred. The reference benchmark of this class is used for performance comparison purposes only (dividend reinvested). No benchmark is directly identical to a sub-fund, thus the performance of a benchmark is not a reliable indicator of future performance of the sub-fund it is compared to. There can be no assurance that a return will be achieved or that a substantial loss of capital will not be incurred. All figures in base currency in %, calculated by the total return / BVI method.Show moreShow less

Ratings

  • Portfolio Manager

    Stefan Blum

    Stefan Blum joined Bellevue Asset Management in 2008 and is portfolio manager of the funds BB Adamant Medtech & Services and BB Adamant Digital Health. Prior to joining Bellevue Asset Management, he spent 4 years as head of investor relations at Sonova. As a financial analyst at Bank Sarasin, he covered medical technology and high tech stocks. After that he served as CFO of Obtree Technologies Inc. Stefan Blum obtained a degree in business administration from the University of St. Gallen and is CEFA charterholder.
  • Portfolio Manager

    Marcel Fritsch

    Marcel Fritsch joined Bellevue Asset Management in 2008 as portfolio manager of the BB Adamant Medtech & Services and BB Adamant Digital Health Fund. Prior to that, he spent more than 3 years as a consultant with Deloitte & Touche. Formulating company strategy, evaluating organizational structures and valuing companies prior to corporate transactions were among his duties in this function. Marcel Fritsch holds a degree in business economics from the University of St. Gallen (HSG).
  • Portfolio Manager

    Cyrill Zimmermann

    Dr. Cyrill Zimmerman is Head of Healthcare Funds & Mandates and a member of the Executive Board of Bellevue Asset Management. He founded Adamant Biomedical Investments in 2001 and managed the investment boutique until its acquisition by Bellevue in 2014. Cyrill Zimmerman holds a PhD from the University of Zurich.
  • Equity Analyst

    Mateusz Niedzwiecki

    Mateusz Niedzwiecki has been a Healthcare Analyst at Bellevue Asset Management since 2021. Before joining Bellevue Asset Management, he worked in general and trauma surgery at the Horgen Hospital and most recently at the department of Urology at the University Hospital Zurich. He holds a degree in medicine from the University of Zurich.
1